Abstract
Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patients age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving the survival and quality of life in patients with advanced prostate cancer. Apoptosis as a genetically regulated process has a critical endpoint that coincides with the therapeutic goal of successful treatment of androgen-dependent and androgen-independent prostate cancer. Opportunities to alter the apoptotic threshold of prostate cancer cells using antisense technology and gene therapy certainly exist, but the scope and extent of their applicability and action depends upon research delineating the many subtleties within the apoptotic pathway. Most epithelial and endothelial cells undergo apoptosis when they loose contact with the extracellular matrix (ECM), via the phenomenon of anoikis. Signaling interaction between growth factor apoptosis-signaling pathways and cellular effectors of anoikis potential and tumor vascularity provides a new molecular basis for optimizing combination approaches for the effective treatment of advanced prostate cancer. Agents that induce epithelial or endothelial cell apoptosis by antagonizing integrin binding are considered for cancer therapy via their ability to inhibit tumor vascularization. This review summarizes the current knowledge of the therapeutic benefit of apoptosis induction within the context of tumor neovascularization inhibition, and provides an insight into the consequences of anoikis induction (by different agents) in targeting angiogenesis in prostate cancer cells.
Keywords: Apoptosis, anoikis, angiogenesis, neovascularization
Current Cancer Drug Targets
Title: Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Volume: 4 Issue: 1
Author(s): Jason B. Garrison and Natasha Kyprianou
Affiliation:
Keywords: Apoptosis, anoikis, angiogenesis, neovascularization
Abstract: Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patients age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving the survival and quality of life in patients with advanced prostate cancer. Apoptosis as a genetically regulated process has a critical endpoint that coincides with the therapeutic goal of successful treatment of androgen-dependent and androgen-independent prostate cancer. Opportunities to alter the apoptotic threshold of prostate cancer cells using antisense technology and gene therapy certainly exist, but the scope and extent of their applicability and action depends upon research delineating the many subtleties within the apoptotic pathway. Most epithelial and endothelial cells undergo apoptosis when they loose contact with the extracellular matrix (ECM), via the phenomenon of anoikis. Signaling interaction between growth factor apoptosis-signaling pathways and cellular effectors of anoikis potential and tumor vascularity provides a new molecular basis for optimizing combination approaches for the effective treatment of advanced prostate cancer. Agents that induce epithelial or endothelial cell apoptosis by antagonizing integrin binding are considered for cancer therapy via their ability to inhibit tumor vascularization. This review summarizes the current knowledge of the therapeutic benefit of apoptosis induction within the context of tumor neovascularization inhibition, and provides an insight into the consequences of anoikis induction (by different agents) in targeting angiogenesis in prostate cancer cells.
Export Options
About this article
Cite this article as:
Garrison B. Jason and Kyprianou Natasha, Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy, Current Cancer Drug Targets 2004; 4 (1) . https://dx.doi.org/10.2174/1568009043481623
DOI https://dx.doi.org/10.2174/1568009043481623 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Proteomic Profiling of a Biomimetic Drug Delivery Platform
Current Drug Targets Hyperpolarized <sup>13</sup>C MR Angiography
Current Pharmaceutical Design Recent Advances in the Chemistry of Phthalimide Analogues and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Radiolabeled Peptides and Proteins in Cancer Therapy
Protein & Peptide Letters Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiating Between Primary Tumor, Metastatic Node and Normal Tissue in Head and Neck Cancer
Current Medical Imaging Anticancer Potential of Thiazole Derivatives: A Retrospective Review
Mini-Reviews in Medicinal Chemistry Effects of Oxymatrine from Ku Shen on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells
Current Cancer Drug Targets Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche
Current Cancer Therapy Reviews HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept
Current Cancer Drug Targets Pediatric Health Effects of Chronic Exposure to Extremely Low Frequency Electromagnetic Fields
Current Pediatric Reviews Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets